A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

Hernandez-Prieto S.; Romera A.; Ferrer M.; Subiza J. L.; Lopez-Asenjo J. A.; Jarabo J. R.; Gomez A. M.; Molina Elena M.; Puente J.; Gonzalez-Larriba J. L.; Hernando F.; Perez-Villamil B.; Diaz-Rubio E.; Sanz-Ortega J.

首页> 外文期刊>Clinical & translational oncology : >A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

【24h】

A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

机译：具有50个基因的特征是一种针对肿瘤浸润免疫细胞的新型评分系统，该评分系统与I / II期非小细胞肺癌的临床结局密切相关

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To identify a novel system for scoring intratumoral immune response that can improve prognosis and therapy decisions in early stage non-small cell lung cancer (NSCLC).

机译：鉴定评分肿瘤内免疫反应的新型系统，该系统可改善早期非小细胞肺癌（NSCLC）的预后和治疗决策。

著录项

来源
《Clinical & translational oncology :》 |2015年第4期|共9页
作者
Hernandez-Prieto S.; Romera A.; Ferrer M.; Subiza J. L.; Lopez-Asenjo J. A.; Jarabo J. R.; Gomez A. M.; Molina Elena M.; Puente J.; Gonzalez-Larriba J. L.; Hernando F.; Perez-Villamil B.; Diaz-Rubio E.; Sanz-Ortega J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Gene expression; Molecular classification; Immune response; Non-small cell lung cancer; Early stages; Relapse-free survival;

机译：基因表达;分子分类;免疫应答;非小细胞肺癌;早期;无复发生存;

相似文献

外文文献
中文文献
专利

1. A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer [J] . Hernandez-Prieto S., Romera A., Ferrer M., Clinical & translational oncology : . 2015,第4期

机译：具有50个基因的特征是一种针对肿瘤浸润免疫细胞的新型评分系统，该评分系统与I / II期非小细胞肺癌的临床结局密切相关
2. Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer [J] . Evelyn E.C. de Jong, Wouter van Elmpt, Stefania Rizzo, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2018,第期

机译：IV阶段非小细胞肺癌阶段I-III非小细胞肺癌训练的预后CT基辐射签名模型的适用性
3. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer [J] . Song Peng, Guo Lei, Li Wenbin, Journal of immunotherapy . 2019,第1期

机译：临床病理相关性与非小细胞肺癌患者肿瘤细胞和肿瘤渗透免疫细胞表达的临床病理学相关性
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer [O] . Yu-Suo Tong, Juan Tan, Xi-Lei Zhou, 2017

机译：全身免疫炎症指数预测III期非小细胞肺癌患者的放化疗耐药性和预后不良
7. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer [O] . Yu-Suo Tong, Juan Tan, Xi-Lei Zhou, 2017

机译：系统性免疫炎症指数预测III期非小细胞肺癌患者的放化疗耐药性和预后不良

A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅